Abstract:Background: Oncogenic mutations in the KRAS gene are detected in >90% of pancreatic cancers (PC). In genetically engineered mouse models of PC, oncogenic KRAS drives the formation of precursor lesions and their progression to invasive PC. The Yes-associated Protein (YAP) is a transcriptional coactivator required for transformation by the RAS oncogenes and the development of PC. In Ras-driven tumors, YAP can also substitute for oncogenic KRAS to drive tumor survival after the repression of the oncogene. Ras oncoproteins exert their transforming properties through their downstream effectors, including the PI3K kinase, Rac1 GTPase, and MAPK pathways. Methods: To identify Ras effectors that regulate YAP, YAP levels were measured in PC cells exposed to inhibitors of oncogenic K-Ras and its effectors. Results: In PC cells, the inhibition of Rac1 leads to a time-dependent decline in YAP protein, which could be blocked by proteosome inhibitor MG132. This YAP degradation after Rac1 inhibition was observed in a range of cell lines using different Rac1 inhibitors, Rac1 siRNA, or expression of dominant negative Rac1T17N mutant. Several E3 ubiquitin ligases, including SCFβTrCP, regulate YAP protein stability. To be recognized by this ligase, the βTrCP degron of YAP (amino acid 383–388) requires its phosphorylation by casein kinase 1 at Ser384 and Ser387, but these events must first be primed by the phosphorylation of Ser381 by LATS1/2. Using Flag-tagged mutants of YAP, we show that YAP degradation after Rac1 inhibition requires the integrity of this degron and is blocked by the silencing of βTrCP1/2 and by the inhibition of casein kinase 1. Unexpectedly, YAP degradation after Rac1 inhibition was still observed after the silencing of LATS1/2 or in cells carrying a LATS1/2 double knockout. Conclusions: These results reveal Rac1 as an oncogenic KRAS effector that contributes to YAP stabilization in PC cells. They also show that this regulation of YAP by Rac1 requires the SCFβTrCP ligase but occurs independently of the LATS1/2 kinases.

PLK1 and Β-Trcp-dependent Ubiquitination and Degradation of Rap1GAP Controls Cell Proliferation

Site-specific Proteasome Phosphorylation Controls Cell Proliferation and Tumorigenesis

Involvement of Polo-like Kinase 1 (plk1) in Mitotic Arrest by Inhibition of Mitogen-activated Protein Kinase-Extracellular Signal-regulated Kinase-Ribosomal S6 Kinase 1

Phosphoproteome Profiling Revealed The Importance Of Mtor Inhibition On Cdk1 Activation To Further Regulate Cell Cycle Progression

A Coordinated Phosphorylation By Lats And Ck1 Regulates Yap Stability Through Scf Beta-Trcp

Involvement of Polo-like Kinase 1 (plk1) in Mitotic Arrest by Inhibition of Mitogen-activated Protein Kinase-Extracellular Signal-regulated Kinase-Ribosomal S6 Kinase 1 (MEK-ERK-RSK1) Cascade*

Polo-like Kinase-1 Triggers Histone Phosphorylation by Haspin in Mitosis.

Regulation of P27kip1 Phosphorylation and G1 Cell Cycle Progression by Protein Phosphatase PPM1G.

Ubiquitylation and Proteasomal Degradation of the P21cip1, P27kip1and P57kip2cdk Inhibitors

The Plk1 Kinase Negatively Regulates The Hedgehog Signaling Pathway By Phosphorylating Gli1

The tumor suppressor RASSF1A is a novel effector of small G protein Rap1A

Plk1-mediated Mitotic Phosphorylation of PinX1 Regulates Its Stability

ULK1 Phosphorylates Mad1 to Regulate Spindle Assembly Checkpoint

Rac1 GTPase Regulates the βTrCP-Mediated Proteolysis of YAP Independently of the LATS1/2 Kinases

Ubiquitylation and Proteasomal Degradation of the P21(Cip1), P27(Kip1) and P57(Kip2) Cdk Inhibitors

PTPN14 is Required for the Density-Dependent Control of YAP1

Tubulin polymerization promoting protein 1 (Tppp1) phosphorylation by Rho-associated coiled-coil kinase (rock) and cyclin-dependent kinase 1 (Cdk1) inhibits microtubule dynamics to increase cell proliferation

The Role of GSK3β in Rapamycin-Mediated Cell Cycle Regulation

Self-priming of Plk1 binding to BubR1 ensures accurate mitotic progression

Interplay of RAP2 GTPase and the cytoskeleton in Hippo pathway regulation

BAP1 regulates AMPK-mTOR signalling pathway through deubiquitinating and stabilizing tumour-suppressor LKB1